1
|
Blanco T, Singh RB, Nakagawa H, Taketani Y, Dohlman TH, Chen Y, Chauhan SK, Yin J, Dana R. Conventional type I migratory CD103 + dendritic cells are required for corneal allograft survival. Mucosal Immunol 2023; 16:711-726. [PMID: 36642378 PMCID: PMC10413378 DOI: 10.1016/j.mucimm.2022.12.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2022] [Accepted: 12/14/2022] [Indexed: 01/15/2023]
Abstract
Corneal transplant rejection primarily occurs because of the T helper 1 (Th1) effector cell-mediated immune response of the host towards allogeneic tissue. The evidence suggests that type 1 migratory conventional CD103+ dendritic cells (CD103+DC1) acquire an immunosuppressive phenotype in the tumor environment; however, the involvement of CD103+DC1 in allograft survival continues to be an elusive question of great clinical significance in tissue transplantation. In this study, we assess the role of CD103+DC1 in suppressing Th1 alloreactivity against transplanted corneal allografts. The immunosuppressive function of CD103+DC1 has been extensively studied in non-transplantation settings. We found that host CD103+DC1 infiltrates the corneal graft and migrates to the draining lymph nodes to suppress alloreactive CD4+ Th1 cells via the programmed death-ligand 1 axis. The systemic depletion of CD103+ DC1 in allograft recipients leads to amplified Th1 activation, impaired Treg function, and increased rate of allograft rejection. Although allograft recipient Rag1 null mice reconstituted with naïve CD4+CD25- T cells efficiently generated peripheral Treg cells (pTreg), the CD103+DC1-depleted mice failed to generate pTreg. Furthermore, adoptive transfer of pTreg failed to rescue allografts in CD103+DC1-depleted recipients from rejection. These data demonstrate the critical role of CD103+DC1 in regulating host alloimmune responses.
Collapse
Affiliation(s)
- Tomas Blanco
- Laboratory of Corneal Immunology, Transplantation, and Regeneration, Schepens Eye Research Institute of Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, USA
| | - Rohan Bir Singh
- Laboratory of Corneal Immunology, Transplantation, and Regeneration, Schepens Eye Research Institute of Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, USA
| | - Hayate Nakagawa
- Laboratory of Corneal Immunology, Transplantation, and Regeneration, Schepens Eye Research Institute of Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, USA
| | - Yukako Taketani
- Laboratory of Corneal Immunology, Transplantation, and Regeneration, Schepens Eye Research Institute of Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, USA
| | - Thomas H Dohlman
- Laboratory of Corneal Immunology, Transplantation, and Regeneration, Schepens Eye Research Institute of Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, USA
| | - Yihe Chen
- Laboratory of Corneal Immunology, Transplantation, and Regeneration, Schepens Eye Research Institute of Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, USA
| | - Sunil K Chauhan
- Laboratory of Corneal Immunology, Transplantation, and Regeneration, Schepens Eye Research Institute of Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, USA
| | - Jia Yin
- Laboratory of Corneal Immunology, Transplantation, and Regeneration, Schepens Eye Research Institute of Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, USA
| | - Reza Dana
- Laboratory of Corneal Immunology, Transplantation, and Regeneration, Schepens Eye Research Institute of Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, USA.
| |
Collapse
|
2
|
Saporin as a Commercial Reagent: Its Uses and Unexpected Impacts in the Biological Sciences—Tools from the Plant Kingdom. Toxins (Basel) 2022; 14:toxins14030184. [PMID: 35324681 PMCID: PMC8952126 DOI: 10.3390/toxins14030184] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2022] [Revised: 02/23/2022] [Accepted: 02/23/2022] [Indexed: 02/02/2023] Open
Abstract
Saporin is a ribosome-inactivating protein that can cause inhibition of protein synthesis and causes cell death when delivered inside a cell. Development of commercial Saporin results in a technology termed ‘molecular surgery’, with Saporin as the scalpel. Its low toxicity (it has no efficient method of cell entry) and sturdy structure make Saporin a safe and simple molecule for many purposes. The most popular applications use experimental molecules that deliver Saporin via an add-on targeting molecule. These add-ons come in several forms: peptides, protein ligands, antibodies, even DNA fragments that mimic cell-binding ligands. Cells that do not express the targeted cell surface marker will not be affected. This review will highlight some newer efforts and discuss significant and unexpected impacts on science that molecular surgery has yielded over the last almost four decades. There are remarkable changes in fields such as the Neurosciences with models for Alzheimer’s Disease and epilepsy, and game-changing effects in the study of pain and itch. Many other uses are also discussed to record the wide-reaching impact of Saporin in research and drug development.
Collapse
|
3
|
Kato J, O'Donnell RT, Abuhay M, Tuscano JM. Efficacy and toxicity of a CD22-targeted antibody-saporin conjugate in a xenograft model of non-Hodgkin's lymphoma. Oncoimmunology 2021; 1:1469-1475. [PMID: 23264893 PMCID: PMC3525602 DOI: 10.4161/onci.21815] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
Antibody drug conjugates (ADCs) can deliver potent drugs to cancer cells by employing the specificity of monoclonal antibodies (mAbs). ADCs have demonstrated significant anticancer activity and, in 2011, brentuximab vedotin has been approved by the FDA for the treatment of Hodgkin's and anaplastic large cell lymphomas. CD22 is an ideal target for ADC against B-cell malignancies because of its lineage-specific expression and rapid internalization upon antibody binding. In this study, we evaluated the anti-CD22 mAb HB22.7 as a vehicle for the targeted delivery of the potent toxin saporin (SAP). In vitro, HB22.7-SAP was cytotoxic against a panel of non-Hodgkin's lymphoma (NHL) cell lines representing the most common types of the disease. Moreover, in a xenograft model of NHL, HB22.7-SAP significantly inhibited the growth of established lesions and completely prevented tumor development when treatment was initiated within 24 h from tumor-cell inoculation. HB22.7-SAP had no significant in vivo toxicity. In conclusion, HB22.7 constitutes a potential platform for CD22-targeted ADCs.
Collapse
Affiliation(s)
- Jason Kato
- Division of Hematology and Oncology; Department of Internal Medicine; University of California, Davis Cancer Center; Sacramento, CA USA
| | | | | | | |
Collapse
|
4
|
Bolognesi A, Bortolotti M, Battelli MG, Polito L. Hyperuricaemia, Xanthine Oxidoreductase and Ribosome-Inactivating Proteins from Plants: The Contributions of Fiorenzo Stirpe to Frontline Research. Molecules 2017; 22:molecules22020206. [PMID: 28134797 PMCID: PMC6155646 DOI: 10.3390/molecules22020206] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2016] [Accepted: 01/23/2017] [Indexed: 11/16/2022] Open
Abstract
The enzymes called ribosome-inactivating proteins (RIPs) that are able to depurinate nucleic acids and arrest vital cellular functions, including protein synthesis, are still a frontline research field, mostly because of their promising medical applications. The contributions of Stirpe to the development of these studies has been one of the most relevant. After a short biographical introduction, an overview is offered of the main results obtained by his investigations during last 55 years on his main research lines: hyperuricaemia, xanthine oxidoreductase and RIPs.
Collapse
Affiliation(s)
- Andrea Bolognesi
- Department of Experimental, Diagnostic and Specialty Medicine-DIMES, Alma Mater Studiorum, University of Bologna, Via San Giacomo 14, 40126 Bologna, Italy.
| | - Massimo Bortolotti
- Department of Experimental, Diagnostic and Specialty Medicine-DIMES, Alma Mater Studiorum, University of Bologna, Via San Giacomo 14, 40126 Bologna, Italy.
| | - Maria Giulia Battelli
- Department of Experimental, Diagnostic and Specialty Medicine-DIMES, Alma Mater Studiorum, University of Bologna, Via San Giacomo 14, 40126 Bologna, Italy.
| | - Letizia Polito
- Department of Experimental, Diagnostic and Specialty Medicine-DIMES, Alma Mater Studiorum, University of Bologna, Via San Giacomo 14, 40126 Bologna, Italy.
| |
Collapse
|
5
|
Bolognesi A, Bortolotti M, Maiello S, Battelli MG, Polito L. Ribosome-Inactivating Proteins from Plants: A Historical Overview. Molecules 2016; 21:molecules21121627. [PMID: 27898041 PMCID: PMC6273060 DOI: 10.3390/molecules21121627] [Citation(s) in RCA: 68] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2016] [Revised: 11/22/2016] [Accepted: 11/23/2016] [Indexed: 12/12/2022] Open
Abstract
This review provides a historical overview of the research on plant ribosome-inactivating proteins (RIPs), starting from the first studies at the end of eighteenth century involving the purification of abrin and ricin, as well as the immunological experiments of Paul Erlich. Interest in these plant toxins was revived in 1970 by the observation of their anticancer activity, which has given rise to a large amount of research contributing to the development of various scientific fields. Biochemistry analyses succeeded in identifying the enzymatic activity of RIPs and allowed for a better understanding of the ribosomal machinery. Studies on RIP/cell interactions were able to detail the endocytosis and intracellular routing of ricin, thus increasing our knowledge of how cells handle exogenous proteins. The identification of new RIPs and the finding that most RIPs are single-chain polypeptides, together with their genetic sequencing, has aided in the development of new phylogenetic theories. Overall, the biological properties of these proteins, including their abortifacient, anticancer, antiviral and neurotoxic activities, suggest that RIPs could be utilized in agriculture and in many biomedical fields, including clinical drug development.
Collapse
Affiliation(s)
- Andrea Bolognesi
- Department of Experimental, Diagnostic and Specialty Medicine-DIMES, Alma Mater Studiorum, University of Bologna, Via San Giacomo 14, 40126 Bologna, Italy.
| | - Massimo Bortolotti
- Department of Experimental, Diagnostic and Specialty Medicine-DIMES, Alma Mater Studiorum, University of Bologna, Via San Giacomo 14, 40126 Bologna, Italy.
| | - Stefania Maiello
- Department of Experimental, Diagnostic and Specialty Medicine-DIMES, Alma Mater Studiorum, University of Bologna, Via San Giacomo 14, 40126 Bologna, Italy.
| | - Maria Giulia Battelli
- Department of Experimental, Diagnostic and Specialty Medicine-DIMES, Alma Mater Studiorum, University of Bologna, Via San Giacomo 14, 40126 Bologna, Italy.
| | - Letizia Polito
- Department of Experimental, Diagnostic and Specialty Medicine-DIMES, Alma Mater Studiorum, University of Bologna, Via San Giacomo 14, 40126 Bologna, Italy.
| |
Collapse
|
6
|
Mang Y, Zhao Z, Zeng Z, Wu X, Li Z, Zhang L. Efficient elimination of CD103-expressing cells by anti-CD103 antibody drug conjugates in immunocompetent mice. Int Immunopharmacol 2014; 24:119-27. [PMID: 25467246 DOI: 10.1016/j.intimp.2014.11.004] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2014] [Revised: 10/29/2014] [Accepted: 11/05/2014] [Indexed: 01/06/2023]
Abstract
CD103 plays an important role in the destruction of islet allografts, and previous studies found that a CD103 immunotoxin (M290-Saporin, or M290-SAP) promoted the long-term survival of pancreatic islet allografts. However, systemic toxicity to the host and the bystander effects of M290-SAP obscure the underlying mechanisms of action and restrict its clinical applications. To overcome these shortcomings, anti-CD103 M290 was conjugated to different cytotoxic agents through cleavable or uncleavable linkages to form three distinct antibody-drug conjugates (ADCs): M290-MC-vc-PAB-MMAE, M290-MC-MMAF, and M290-MCC-DM1. The drug-to-antibody ratio (DAR) and the purity of the ADCs were determined by HIC-HPLC and SEC-HPLC, respectively. The binding characteristics, internalization and cytotoxicity of M290 and the corresponding ADCs were evaluated in vitro. The cell depletion efficacies of the various M290-ADCs against CD103-positive cells were then evaluated in vivo. The M290-ADCs maintained the initial binding affinity for the CD103-positive cell surface antigen and then quickly internalized the CD103-positive cell. Surprisingly, all M290-ADCs potently depleted CD103-positive cells in vivo, with high specificity and reduced toxicity. Our findings show that M290-ADCs have potent and selective depletion effects on CD103-expressing cells in immunocompetent mice. These data indicate that M290-ADCs could potentially serve as a therapeutic intervention to block the CD103/E-cadherin pathway.
Collapse
Affiliation(s)
- Yuanyi Mang
- Department of General Surgery, The 2nd Affiliated Hospital of Harbin Medical University, 246 Xufu Road, Harbin, Heilongjiang Province 150086, China
| | - Zhihui Zhao
- Department of General Surgery, The 2nd Affiliated Hospital of Harbin Medical University, 246 Xufu Road, Harbin, Heilongjiang Province 150086, China
| | - Zhaolin Zeng
- Department of General Surgery, The 2nd Affiliated Hospital of Harbin Medical University, 246 Xufu Road, Harbin, Heilongjiang Province 150086, China
| | - Xing Wu
- Department of General Surgery, The 2nd Affiliated Hospital of Harbin Medical University, 246 Xufu Road, Harbin, Heilongjiang Province 150086, China
| | - Zhengjie Li
- Department of General Surgery, The 2nd Affiliated Hospital of Harbin Medical University, 246 Xufu Road, Harbin, Heilongjiang Province 150086, China
| | - Lei Zhang
- Department of General Surgery, The 2nd Affiliated Hospital of Harbin Medical University, 246 Xufu Road, Harbin, Heilongjiang Province 150086, China.
| |
Collapse
|
7
|
Jeon YK, Min HS, Lee YJ, Kang BH, Kim EJ, Park HJ, Bae Y, Lee HG, Park WS, Song HG, Jung KC, Park SH. Targeting of a developmentally regulated epitope of CD43 for the treatment of acute leukemia. Cancer Immunol Immunother 2011; 60:1697-706. [PMID: 21710258 PMCID: PMC11028941 DOI: 10.1007/s00262-011-1066-7] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2010] [Accepted: 06/14/2011] [Indexed: 02/02/2023]
Abstract
Previously, we developed a JL1 mouse monoclonal antibody that specifically recognizes the leukemic cells of T, B, and myeloid lineages, but not the peripheral blood cells and pluripotent hematopoietic stem cells. Here, we identified that JL1 mAb recognized a specific epitope of human CD43 and validated its potential as an anti-leukemic targeting agent. After the comprehensive screening of JL1 Ag in the human thymocyte cDNA library, multiple fusion gene constructs encoding human CD43 were generated to identify its specific epitope to JL1 antibody. JL1 antibody interacted with a developmentally regulated and non-glycosylated epitope of the human CD43 extracellular domain (AA 73-81, EGSPLWTSI). In an in vivo leukemia model using NOD/SCID mice injected with CCRF-CEM7 cells, JL1 antibody induced effective cytotoxicity in tumor cells and prolonged survival (p < 0.05). Saporin conjugation to JL1 antibody effectively depleted tumor cells in in vitro cytotoxic assays and also prolonged survival in a leukemic mouse model (p < 0.001). These preclinical results further support the therapeutic potential of the JL1 antibody in the management of acute leukemia.
Collapse
MESH Headings
- Animals
- Antibodies, Monoclonal/immunology
- Antibodies, Monoclonal/therapeutic use
- Blotting, Western
- Cell Separation
- Disease Models, Animal
- Epitopes, B-Lymphocyte/immunology
- Flow Cytometry
- Humans
- Leukemia, Biphenotypic, Acute/drug therapy
- Leukemia, Biphenotypic, Acute/immunology
- Leukosialin/immunology
- Mice
- Mice, Inbred NOD
- Mice, SCID
- Real-Time Polymerase Chain Reaction
Collapse
Affiliation(s)
- Yoon Kyung Jeon
- Department of Pathology, Seoul National University College of Medicine, Seoul, 110-799 Korea
| | - Hye Sook Min
- Department of Pathology, Seoul National University College of Medicine, Seoul, 110-799 Korea
- Dinona Inc., Seoul, Korea
| | - Yoo Jeong Lee
- Department of Pathology, Seoul National University College of Medicine, Seoul, 110-799 Korea
- Graduate Program of Immunology, Seoul National University College of Medicine, Seoul, Korea
| | - Byung Hyun Kang
- Department of Biomedical Science, Seoul National University College of Medicine, Seoul, Korea
| | - Eun Ji Kim
- Graduate Program of Immunology, Seoul National University College of Medicine, Seoul, Korea
| | - Hyo Jin Park
- Department of Pathology, Seoul National University Bundang Hospital, Bundang, Korea
| | - Youngmee Bae
- Department of Parasitology and Tropical Medicine, Seoul National University College of Medicine, Seoul, Korea
| | - Hyun Gyu Lee
- Department of Pathology, Seoul National University College of Medicine, Seoul, 110-799 Korea
- Graduate Program of Immunology, Seoul National University College of Medicine, Seoul, Korea
| | - Weon Seo Park
- Department of Pathology and Research Center for Hematopoietic Tumor, National Cancer Center, Goyang, Korea
| | - Hyung Geun Song
- Dinona Inc., Seoul, Korea
- Department of Pathology, Chungbuk National University, Cheongju, Korea
| | - Kyeong Cheon Jung
- Department of Pathology, Seoul National University College of Medicine, Seoul, 110-799 Korea
- Dinona Inc., Seoul, Korea
- Graduate Program of Immunology, Seoul National University College of Medicine, Seoul, Korea
| | - Seong Hoe Park
- Department of Pathology, Seoul National University College of Medicine, Seoul, 110-799 Korea
- Graduate Program of Immunology, Seoul National University College of Medicine, Seoul, Korea
| |
Collapse
|
8
|
Pain is a salient "stressor" that is mediated by corticotropin-releasing factor-1 receptors. Neuropharmacology 2010; 59:160-6. [PMID: 20470804 DOI: 10.1016/j.neuropharm.2010.05.001] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2010] [Revised: 04/20/2010] [Accepted: 05/04/2010] [Indexed: 12/19/2022]
Abstract
Corticotropin-releasing factor (CRF) plays a major role in controlling the body's response to stress. Because painful conditions are inherently stressful, we hypothesize that CRF may act via CRF-1 receptors to contribute to the pain experience. Studies were designed to investigate whether blocking CRF-1 receptors with selective antagonists or reducing their expression with CRF-Saporin, would attenuate ulcer, inflammatory- and neuropathic-like pain. Five experimental designs were undertaken. In experiment 1, ulcer pain was induced in mice following oral administration of indomethacin, while in experiments 2 and 3, inflammatory pain was induced in rats with either carrageenan or FCA, respectively. For these studies, animals were dosed with CP-154,526 (3, 10, 30 mg/kg) and NBI 27914 (1-30 mg/kg) 1 h prior to the assessment of tactile, thermal or mechanical hypersensitivity, respectively. In experiment 4, neuropathic pain was induced. Twenty-one days following spinal nerve ligation (SNL), animals received CRF-Saporin or control. Three weeks later tactile allodynia was assessed. Similarly, in experiment 5, a separate set of rats received CRF-Saporin or control. Twenty-one days later, mechanical hyperalgesia was assessed following intraplantar carrageenan. Results from the antagonist studies showed that CP-154,526 and NBI 27914 either fully or partially reversed the referred ulcer pain with minimal effective doses (MED) equal to 3 and 10 mg/kg, respectively. Similarly, both NBI 27914 and CP-154,526 reversed the thermal and mechanical hypersensitivity elicited by carrageenan and FCA with MEDs </= 5 and 10 mg/kg, respectively. Findings from the two CRF-Saporin studies determined that pre-treatment with this toxin significantly attenuated SNL- and carrageenan-induced tactile hypersensitivity. Together, these findings suggest that CRF-1 receptors mediate pain and implicate CRF in this regard.
Collapse
|
9
|
Zhang L, Moffatt-Bruce SD, Gaughan AA, Wang JJ, Rajab A, Hadley GA. An anti-CD103 immunotoxin promotes long-term survival of pancreatic islet allografts. Am J Transplant 2009; 9:2012-23. [PMID: 19645708 PMCID: PMC3190194 DOI: 10.1111/j.1600-6143.2009.02735.x] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Previous studies using knockout mice document a key role for the integrin CD103 in promoting organ allograft rejection and graft-versus-host disease. However, a determination of whether blockade of the CD103 pathway represents a viable therapeutic strategy for intervention in these processes has proven problematic due to the lack of reagents that efficiently deplete CD103+ cells from wild type hosts. To circumvent this problem, we conjugated the nondepleting anti-CD103 monoclonal antibody, M290, to the toxin, saporin, to produce an immunotoxin (M290-SAP) that efficiently depletes CD103+ cells in vivo. Herein, we show that M290-SAP dramatically reduces the frequency and absolute numbers of CD103-expressing leukocytes in the blood, spleen, mesenteric lymph nodes and intestinal epithelium of treated mice. We further demonstrate that M290-SAP promotes indefinite islet allograft survival in a fully MHC mismatched mouse model. The prolonged islet allograft survival resulting from M290-SAP treatment was associated with multiple effects in the host immune system including not only depletion of CD103-expressing leukocytes, but also an increase in CD4+CD25+FoxP3+ T regulatory cells and a predominance of effector-memory CD8 T cells. Regardless of the underlying mechanisms, these data document that depletion of CD103-expressing cells represents a viable strategy for therapeutic intervention in allograft rejection.
Collapse
Affiliation(s)
- Lei Zhang
- Division of Transplantation, Department of Surgery, The Ohio State University Medical Center, Columbus, Ohio, 43210,Department of General Surgery, Harbin Medical University, Harbin, China 150086
| | - Susan D. Moffatt-Bruce
- Division of Cardiothoracic Surgery, Department of Surgery, The Ohio State University Medical Center, Columbus, Ohio, 43210
| | - Alice A. Gaughan
- Division of Transplantation, Department of Surgery, The Ohio State University Medical Center, Columbus, Ohio, 43210
| | - Jiao-Jing Wang
- Division of Transplantation, Department of Surgery, The Ohio State University Medical Center, Columbus, Ohio, 43210
| | - Amer Rajab
- Division of Transplantation, Department of Surgery, The Ohio State University Medical Center, Columbus, Ohio, 43210
| | - Gregg A. Hadley
- Division of Transplantation, Department of Surgery, The Ohio State University Medical Center, Columbus, Ohio, 43210
| |
Collapse
|
10
|
Hess PR, Barnes C, Woolard MD, Johnson MDL, Cullen JM, Collins EJ, Frelinger JA. Selective deletion of antigen-specific CD8+ T cells by MHC class I tetramers coupled to the type I ribosome-inactivating protein saporin. Blood 2007; 109:3300-7. [PMID: 17179221 PMCID: PMC1852243 DOI: 10.1182/blood-2006-06-028001] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2006] [Accepted: 12/12/2006] [Indexed: 01/26/2023] Open
Abstract
CD8+ cytotoxic T lymphocytes (CTLs) are important effector cells responsible for tissue destruction in several autoimmune and allograft-related diseases. To discover if pathogenic T cells could be selectively deleted, we investigated the ability of a toxin coupled to major histocompatibility complex (MHC) class I tetramers to kill antigen-specific CD8+ T cells. H2-D(b) tetramers were assembled using streptavidin conjugated to the ribosome-inactivating protein (RIP) saporin (SAP). These tetramers inhibited ribosome activity in vitro, retained the T-cell receptor (TCR)-binding specificity of their nontoxic counterparts, and were internalized by 100% of target cells, leading to cell death in 72 hours. Cytotoxicity was dependent on the tetramer dose and avidity for the T cell. A single injection of the SAP-coupled tetramer eliminated more than 75% of cognate, but not control, T cells. This work demonstrates the therapeutic potential of cytotoxic tetramers to selectively eradicate pathogenic clonotypes while leaving overall T-cell immunity intact.
Collapse
Affiliation(s)
- Paul R Hess
- Department of Microbiology and Immunology, Universaity of North Carolina, Chapel Hill, NC, USA.
| | | | | | | | | | | | | |
Collapse
|
11
|
Allen JW, Mantyh PW, Horais K, Tozier N, Rogers SD, Ghilardi JR, Cizkova D, Grafe MR, Richter P, Lappi DA, Yaksh TL. Safety Evaluation of Intrathecal Substance P-Saporin, a Targeted Neurotoxin, in Dogs. Toxicol Sci 2006; 91:286-98. [PMID: 16500924 DOI: 10.1093/toxsci/kfj143] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Intrathecal (IT) substance P-Saporin (SP-SAP), a 33-kDa-targeted neurotoxin, produces selective destruction of superficial neurokinin 1 receptor (NK1r)-bearing cells in the spinal dorsal horn. In rats, SP-SAP prevents the formation of hyperalgesia and can reverse established neuropathic pain behavior in rodents. To determine the safety of this therapeutic modality in a large animal model, beagles received bolus IT lumbar injections of vehicle, SP-SAP (1.5, 15, 45, or 150 microg), or a nontargeted preparation of saporin (SAP, 150 microg) for immunohistological analysis of spinal cords. Doses of 15 microg SP-SAP and above produced a significant and equivalent loss of NK1r-bearing cells and dendrites in lumbar laminae II and I compared to vehicle- or SAP-treated animals. Cervical regions in all animals displayed no loss of NK1r immunoreactivity as compared to controls. Total numbers of neurons in the lumbar dorsal horn or alpha-motor neurons in the ventral horn demonstrated no significant changes. No increases in the astrocytic marker glial fibrillary acidic protein were noted following treatment with SP-SAP, suggesting a lack of generalized neurotoxicity. Additional dogs received doses of 1.5-150 microg SP-SAP or SAP and were sacrificed after 28 or 90 days to assess behavioral and physiological parameters. Although some acute motor signs were observed with both SP-SAP and SAP, no long-lasting significant events were noted in any of these animals. These data indicate no adverse toxicity at doses up to 10 times those necessary for producing loss of superficial NK1r-bearing neurons in a large animal model.
Collapse
Affiliation(s)
- Jeffrey W Allen
- Department of Anesthesiology, University of California, San Diego, La Jolla, California 92093-0818, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Rustamzadeh E, Hall WA, Todhunter DA, Low WC, Liu H, Panoskaltsis-Mortari A, Vallera DA. Intracranial therapy of glioblastoma with the fusion protein DTIL13 in immunodeficient mice. Int J Cancer 2006; 118:2594-601. [PMID: 16358262 DOI: 10.1002/ijc.21647] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
A fusion protein consisting of human interleukin-13 and the first 389 amino acids of diphtheria toxin was assembled in order to target human glioblastoma cell lines in a murine intracranial model. In vitro studies to determine specificity indicated that the protein called DTIL13 was highly selective for human glioblastoma. In vivo, the maximum tolerated dose of DTIL13 was 1 microg/injection given every other day and repeated for 3 days. Doses that exceeded this amount resulted in weight loss and liver damage as determined by histology and enzyme assay. Experiments in IL-4 receptor knockout mice revealed that liver toxicity was receptor-related. This same dose given to nude mice with established U373 MG brain tumors resulted in significant reductions in tumor volume and significantly prolonged survival (p<0.0001). Magnetic resonance imaging (MRI) proved to be extremely useful in (i) determining the ability of DTIL13 to reduce tumor size and (ii) for studying toxicity since diffusion-weighted and gradient echo-weighted MRI revealed that vascular leak syndrome was not a limiting toxicity at this dose. These results suggest that DTIL13 is as effective in an intracranial rodent model as it was in a flank model in previous studies and that DTIL13 might be an effective treatment for glioblastoma multiforme.
Collapse
Affiliation(s)
- Edward Rustamzadeh
- Department of Neurosurgery, University of Minnesota Cancer Research Center, Minneapolis, MN 55455, USA
| | | | | | | | | | | | | |
Collapse
|
13
|
Maciejewski-Lenoir D, Heinrichs SC, Liu XJ, Ling N, Tucker A, Xie Q, Lappi DA, Grigoriadis DE. Selective impairment of corticotropin-releasing factor1 (CRF1) receptor-mediated function using CRF coupled to saporin. Endocrinology 2000; 141:498-504. [PMID: 10650928 DOI: 10.1210/endo.141.2.7336] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
CRF is the main component in the brain neuropeptide effector system responsible for the behavioral, endocrine, and physiological activation that accompanies stress activation. Reduced CRF system activation plays a role in the etiology of a variety of psychiatric and metabolic disease states. We have developed a novel protein conjugate that joins native rat/human CRF to a ribosome-inactivating protein, saporin (CRF-SAP), for the purpose of targeted inactivation of CRF receptor-expressing cells. Cytotoxicity measurements revealed that CRF-SAP (1-100 nM) produced concentration-dependent and progressive cell death over time in CRF1 receptor-transfected L cells, but at similar concentrations had no effect on CRF2alpha receptor-transfected cells. The CRF-SAP-induced toxicity in CRF1-transfected cells was prevented by coincubation with the competitive CRF1/CRF2 receptor peptide antagonist, [D-Phe12]CRF-(12-41), or the selective nonpeptide CRF1 receptor antagonist, NBI 27914. Finally, in cultured rat pituitary cells that express native CRF1 receptors, CRF-SAP suppressed CRF-induced (1 nM) ACTH release. GnRH (1-10 nM) stimulated LH release was also assessed in the same pituitary cultures. Although there was a slight decrease in LH release from these cultures, this decrease was observed with CRF-SAP or SAP alone, suggesting that the response was nonspecific. Taken together, these results suggest the utility of CRF-SAP as a specific and subtype-selective tool for long term impairment of CRF1 receptor-expressing cells.
Collapse
|
14
|
Tang NL, Chan WL, Ke YO, Mak MK, Lai FM, Tam SC. Acute renal failure and proximal tubule lesions after trichosanthin injection in rats. Exp Mol Pathol 1997; 64:78-89. [PMID: 9316586 DOI: 10.1006/exmp.1997.2210] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
The structural basis of the recently recognized renal impairment after infusion of trichosanthin (TCS), a type I ribosome inactivating protein, is uncertain, but functionally it appears to be related to a lesion in the renal tubules. In this study, renal dysfunction in experimental rats was induced by a single dose of TCS. Creatinine clearance and tubular proteinuria were used to assess renal function. Light microscopy and ultrastructure of the kidneys were examined and apoptosis in proximal tubules was evaluated by the in situ TdT-mediated nick end labeling technique. TCS-treated rats demonstrated a significant dose-dependent decrease in creatinine clearance together with a mild degree of low-molecular-weight proteinuria. The proximal convoluted tubule was the site of lesions showing individual tubular cell death, which was more abundant in rats receiving high doses of TCS. Apoptotic cell death, together with heterophagosomes and large residual bodies, was observed. DNA fragmentation was confirmed by the in situ technique. There was also a dose-dependent density of apoptotic cells. Other portions of the nephron were spared, and it was not accompanied by any inflammatory infiltrate. In conclusion, these findings are consistent with TCS-induced proximal tubular toxicity resulting in reduction of glomerular filtration rate and tubular proteinuria. The extent of injury is dosage dependent. Both necrotic cell death and apoptosis participated in the loss of cells from the proximal tubules. Such toxicity may be mediated through intracellular events induced by trichosanthin.
Collapse
Affiliation(s)
- N L Tang
- Department of Physiology, Chinese University of Hong Kong, Hong Kong
| | | | | | | | | | | |
Collapse
|
15
|
Bolognesi A, Tazzari PL, Olivieri F, Polito L, Falini B, Stirpe F. Induction of apoptosis by ribosome-inactivating proteins and related immunotoxins. Int J Cancer 1996; 68:349-55. [PMID: 8903477 DOI: 10.1002/(sici)1097-0215(19961104)68:3<349::aid-ijc13>3.0.co;2-3] [Citation(s) in RCA: 71] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Immunotoxins have been prepared with 3 ribosome-inactivating proteins (RIPs), namely, momordin, pokeweed anti-viral protein from seeds (PAP-S) and saporin, linked to the Ber-H2 monoclonal antibody directed against the CD30 antigen of human lymphocytes. Either the RIPs or the immunotoxins induced apoptosis in the CD30+ L540 cell line, as shown by the morphological aspects of the cells, by the DNA fragmentation visible at the electrophoresis, and by the formation of DNA breaks evidenced by 2 cytofluorometric techniques (propidium-iodide staining and fluoresceine-isothiocyanate conjugate dUTP incorporation). The AC50 (concentration causing apoptosis in 50% of the cells) is in the range 10(-8) to 10(-7) M in the case of RIPs, and 10(-11) to 10(-10) M in the case of the immunotoxins.
Collapse
MESH Headings
- Antibodies, Monoclonal/immunology
- Antibodies, Monoclonal/pharmacology
- Antimetabolites, Antineoplastic/pharmacology
- Antineoplastic Agents, Phytogenic/pharmacology
- Apoptosis/drug effects
- Apoptosis/physiology
- DNA, Neoplasm/analysis
- DNA, Neoplasm/genetics
- DNA, Neoplasm/metabolism
- Flow Cytometry
- Fluorescence
- Hodgkin Disease/drug therapy
- Hodgkin Disease/metabolism
- Hodgkin Disease/pathology
- Humans
- Immunotoxins/pharmacology
- Ki-1 Antigen/immunology
- Leucine/metabolism
- N-Glycosyl Hydrolases
- Plant Proteins/pharmacology
- Ribosome Inactivating Proteins, Type 1
- Ribosome Inactivating Proteins, Type 2
- Ribosomes/drug effects
- Saporins
- Tritium
- Tumor Cells, Cultured
Collapse
Affiliation(s)
- A Bolognesi
- Dipartimento di Patologia Sperimentale, Università Bologna, Italy
| | | | | | | | | | | |
Collapse
|
16
|
Barbieri L, Valbonesi P, Gorini P, Pession A, Stirpe F. Polynucleotide: adenosine glycosidase activity of saporin-L1: effect on DNA, RNA and poly(A). Biochem J 1996; 319 ( Pt 2):507-13. [PMID: 8912688 PMCID: PMC1217797 DOI: 10.1042/bj3190507] [Citation(s) in RCA: 64] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
The ribosome-inactivating proteins (RIPs) are a family of plant enzymes for which a unique activity has been determined: rRNA N-glycosidase, which removes adenine at a specific universally conserved position (A4324 in the case of rat ribosomes). Here we report that saporin-L1, a RIP from the leaves of Saponaria officinalis, recognizes other substrates, including RNAs from different sources, DNA and poly(A). Saporin-L1 depurinated DNA extensively and released adenine from all adenine-containing polynucleotides tested. Adenine was the only base released from DNA or artificial polynucleotides. The characteristics of the reactions catalysed by saporin-L1 have been determined: optimal pH and temperature, ionic requirements, and the kinetic parameters Km and kcat. The reaction proceeded without cofactors, at low ionic strength, in the absence of Mg2+ and K+. Saporin-L1 had no activity towards various adenine-containing non-polynucleotide compounds (cytokinins, cofactors, nucleotides). This plant protein may now be classified as a polynucleotide: adenosine glycosidase.
Collapse
Affiliation(s)
- L Barbieri
- Dipartimento di Patologia sperimentale dell'Università degli Studi di Bologna, Italy
| | | | | | | | | |
Collapse
|
17
|
French RR, Bell AJ, Hamblin TJ, Tutt AL, Glennie MJ. Response of B-cell lymphoma to a combination of bispecific antibodies and saporin. Leuk Res 1996; 20:607-17. [PMID: 8795695 DOI: 10.1016/0145-2126(96)00007-0] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Observations are described using a combination of two bispecific F(ab')2 antibodies (BsAb) to deliver the ribosome-inactivating protein, saporin, in the treatment of low-grade, end-stage, B-cell lymphoma. Two BsAb were used, each having one arm directed at saporin and one at the CD22 on target B cells. The BsAb, however, recognized different, non-overlapping epitopes on each molecule, a strategy which permits high-avidity double attachment of saporin to the target. The BsAb and saporin were pre-mixed at a molar ratio of 3:1 24 h before treatment and infused intravenously over a period of 1 h. Five patients have been treated, mostly with weekly doses of between 2 and 4 mg of saporin for a period of up to 6 weeks. Toxicity was minimal. Three complained of weakness and myalgia for 1 to 2 days after treatment, without objective neurological deficit or rise in serum creatine kinase. One patient produced an anti-mouse Fab' and an anti-saporin response. All patients showed a rapid and beneficial response to treatment. When present, circulating tumor cells were cleared (4/4 patients), ascitic and pleural effusions were eliminated (2/2 patients) and one patient with splenomegaly showed a marked reduction in tumor bulk. Malignant lymph nodes showed significant, but partial, shrinkage in all patients and finally marrow responded well with tumor clearance in biopsy material and impressive resolution of pancytopenia in some patients. While these responses were mainly short-lived, with tumor progression once the treatment was stopped, their speed and magnitude, and the relative lack of associated toxicity warrants further study of this treatment to determine maximum tolerated doses and therapeutic utility.
Collapse
MESH Headings
- Aged
- Antibodies, Bispecific/adverse effects
- Antibodies, Bispecific/pharmacokinetics
- Antibodies, Bispecific/therapeutic use
- Antigens, CD/immunology
- Antigens, CD19/immunology
- Antigens, Differentiation, B-Lymphocyte/immunology
- Antineoplastic Agents, Phytogenic/adverse effects
- Antineoplastic Agents, Phytogenic/pharmacokinetics
- Antineoplastic Agents, Phytogenic/therapeutic use
- Cell Adhesion Molecules
- Female
- Humans
- Immunoglobulin Fab Fragments/adverse effects
- Immunoglobulin Fab Fragments/metabolism
- Immunoglobulin Fab Fragments/therapeutic use
- Immunophenotyping
- Immunotoxins/adverse effects
- Immunotoxins/pharmacokinetics
- Immunotoxins/therapeutic use
- Lectins
- Lymphocyte Count
- Lymphoma, B-Cell/immunology
- Lymphoma, B-Cell/therapy
- Male
- Metabolic Clearance Rate
- Middle Aged
- N-Glycosyl Hydrolases
- Plant Proteins/adverse effects
- Plant Proteins/pharmacokinetics
- Plant Proteins/therapeutic use
- Ribosome Inactivating Proteins, Type 1
- Saporins
- Sialic Acid Binding Ig-like Lectin 2
- Spleen/diagnostic imaging
- Spleen/immunology
- Tomography, X-Ray Computed
Collapse
Affiliation(s)
- R R French
- Lymphoma Research Unit, Tenovus Research Laboratory, Southampton General Hospital, U.K
| | | | | | | | | |
Collapse
|
18
|
Battelli MG, Buonamici L, Bolognesi A, Stirpe F. In vivo and in vitro uptake of an anti-CD30/saporin immunotoxin by rat liver parenchymal and nonparenchymal cells. Hepatology 1994; 20:940-7. [PMID: 7927236 DOI: 10.1002/hep.1840200424] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
A Ber-H2/saporin immunotoxin, consisting of the single-chain ribosome-inactivating protein saporin-S6 and the anti-CD30 monoclonal antibody Ber-H2, gave encouraging results in the treatment of refractory Hodgkin's disease but caused a transient hepatotoxicity. The accumulation of Ber-H2/saporin conjugate and of its components by rat liver parenchymal and nonparenchymal cells was studied. The in vivo concentration of intravenously injected Ber-H2/saporin, saporin or Ber-H2 in nonparenchymal cells was 4-, 25- and 11-fold higher, respectively, than that in parenchymal cells. Adherent in vitro cultured nonparenchymal cells, mostly Kupffer cells, accumulated the proteins approximately 10 times more than parenchymal cells; traces of free saporin were taken up by both types of cells. In vitro protein synthesis by both cell types was inhibited by 50% at nanomolar concentrations of saporin. Nonparenchymal cells were sensitive to Ber-H2/saporin at picomolar concentrations, whereas parenchymal cells were unaffected by the immunotoxin up to 100 pmol/L. The results of the uptake of, and the sensitivity to, the immunotoxin suggest that the sensitivity of liver cells is proportional to the uptake and that the in vivo damage to parenchymal cells is at least in part mediated by the toxicity to nonparenchymal liver cells.
Collapse
Affiliation(s)
- M G Battelli
- Dipartimento di Patologia Sperimentale, Università di Bologna, Italy
| | | | | | | |
Collapse
|
19
|
Dosio F, Brusa P, Delprino L, Grosa G, Ceruti M, Cattel L. A new approach in the synthesis of immunotoxins: ribosome inactivating protein noncovalently bound to monoclonal antibody. J Pharm Sci 1994; 83:206-11. [PMID: 8169790 DOI: 10.1002/jps.2600830218] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
This study describes the synthesis of a new generation of immunotoxins made by a noncovalent interaction between a monoclonal antibody derivatized with a dichlorotriazinic dye and the ribosomal inhibitor protein gelonin. The scheme of preparation has several advantages with respect to the traditional methods, which used heterobifunctional cross-linkers, such as a higher overall yield of production and the homogeneity of the obtained conjugate. Moreover, because no chemical derivatization of the gelonin was required, the unconjugated ribosome inactivating protein was recovered unaltered and therefore can be reused in other synthetic processes. This immunoconjugate was stable when tested in mouse serum and showed an interesting slow elimination rate when administered intravenously in mice. Although a high dye derivatization degree induced a modification of the specificity of the monoclonal antibody, the native specificity was restored after conjugation with gelonin. Furthermore the noncovalent linkage did not affect the gelonin inhibitory activity; in fact, the specific cytotoxic activity seemed to be similar to that of other disulfide-linked immunotoxins previously prepared in our laboratories.
Collapse
MESH Headings
- Animals
- Antibodies, Monoclonal/chemistry
- Antibodies, Monoclonal/immunology
- Antibodies, Neoplasm/chemistry
- Antibodies, Neoplasm/immunology
- Antibody Specificity
- Antigens, Neoplasm/chemistry
- Antigens, Neoplasm/immunology
- Cell-Free System
- Chromatography, Gel
- Drug Carriers
- Enzyme-Linked Immunosorbent Assay
- Female
- Humans
- Immunotoxins/chemistry
- Immunotoxins/metabolism
- Mice
- Mice, Inbred BALB C
- Neoplasm Proteins/biosynthesis
- Plant Proteins/chemistry
- Plant Proteins/immunology
- Protein Synthesis Inhibitors/chemistry
- Protein Synthesis Inhibitors/immunology
- Ribosome Inactivating Proteins, Type 1
- Tobacco Mosaic Virus/drug effects
- Tobacco Mosaic Virus/metabolism
- Triazines
- Tumor Cells, Cultured
- Viral Proteins/biosynthesis
Collapse
Affiliation(s)
- F Dosio
- Istituto di Chimica Farmaceutica Applicata, Torino, Italy
| | | | | | | | | | | |
Collapse
|
20
|
Barbieri L, Battelli MG, Stirpe F. Ribosome-inactivating proteins from plants. BIOCHIMICA ET BIOPHYSICA ACTA 1993; 1154:237-82. [PMID: 8280743 DOI: 10.1016/0304-4157(93)90002-6] [Citation(s) in RCA: 546] [Impact Index Per Article: 17.6] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Affiliation(s)
- L Barbieri
- Dipartimento di Patologia Sperimentale, Università di Bologna, Italy
| | | | | |
Collapse
|
21
|
Falini B, Bolognesi A, Flenghi L, Tazzari PL, Broe MK, Stein H, Dürkop H, Aversa F, Corneli P, Pizzolo G. Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin. Lancet 1992; 339:1195-6. [PMID: 1349939 DOI: 10.1016/0140-6736(92)91135-u] [Citation(s) in RCA: 167] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
In Hodgkin's disease, Hodgkin and Reed-Sternberg cells consistently express the antigen CD30. We investigated the possible therapeutic role of an immunotoxin prepared by covalent linking of an anti-CD30 monoclonal antibody (Ber-H2) to saporin (SO6), a type-1 ribosome-inactivating protein. The immunotoxin (0.8 mg/kg in one or two doses) was given to four patients with advanced refractory Hodgkin's disease. In three, there was rapid and substantial reduction in tumour mass (50% to greater than 75%). Clinical responses were transient (6-10 weeks). In-vivo binding of the immunotoxin to tumour cells was shown by immunohistology in two patients. Antibodies to both parts of the immunotoxin developed in all patients.
Collapse
Affiliation(s)
- B Falini
- Institute of Haematology, University of Perugia, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Brusa P, Dosio F, Pietribiasi F, Delprino L, Feraiorni P, Mariani M, Bussolati G, Cattel L. Antitumour activity of a sterically blocked ricin immunotoxin on a human colorectal adenocarcinoma grafted subcutaneously in nude mice. Cancer Immunol Immunother 1992; 35:373-80. [PMID: 1394342 PMCID: PMC11038090 DOI: 10.1007/bf01789015] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/1992] [Accepted: 06/09/1992] [Indexed: 12/26/2022]
Abstract
We prepared a ricin-antibody conjugate, lacking the ability to bind the galactosidic residues of Sepharose 6B, a so-called blocked immunotoxin. The monoclonal antibody AR-3 was cross-linked to ricin through a thioether bond. Further studies showed that the immunoconjugate suppressed the tumour growth of HT-29 cells in intraperitoneally grafted nude mice, without showing any undesirable ricin toxicity. In this work, to demonstrate the therapeutic activity of the AR-3-ricin conjugate injected into mice bearing subcutaneous tumour, we first evalauted its pharmacokinetic behaviour and biodistribution. The behaviour of the immunoconjugate injected intravenously was almost intermediate between that of the antibody and ricin. Moreover, when the immunotoxin was intravenously administered to nude mice bearing subcutaneous tumour, no therapeutic effects appeared, in accordance with the relatively low permeability of the immunotoxin from the blood to the skin. In contrast, peritumoral treatment produced a strong reduction of the neoplastic nodules without substantial regrowth of the malignant cells. This result was also achieved when the immunotoxin treatment was performed on a well-established tumour. This finding was strictly related to the specifcity of the immunoconjugate, since the analogous treatment with an irrelevant immunotoxin showed therapeutic failure.
Collapse
Affiliation(s)
- P Brusa
- Istituto di Chimica Farmaceutica Applicata, Torino, Italy
| | | | | | | | | | | | | | | |
Collapse
|
23
|
Urch CE, George AJ, Stevenson GT, Bolognesi A, Stirpe F, Weller R, Glennie MJ. Intra-thecal treatment of leptomeningeal lymphoma with immunotoxin. Int J Cancer 1991; 47:909-15. [PMID: 2010234 DOI: 10.1002/ijc.2910470621] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
An animal model has been established to investigate the effect of intra-thecal (i.t.) immunotoxins in the treatment of leptomeningeal metastases of acute lymphoblastic leukaemia (ALL). Direct inoculation of L2C lymphoma cells into the cisterna magna of guinea-pigs gives rise to a leptomeningeal pattern of growth, similar to that of human ALL, and to a systemic leukaemia which develops in approximately 14 days. In our model the systemic disease could be controlled with cyclophosphamide while the meningeal disease progressed and provided a target for i.t. immunotoxin. The immunotoxin used consisted of an anti-idiotypic antibody disulphide-bonded to the ribosome-inactivating protein saporin. It was highly cytotoxic to L2C cells in vitro, being around 30,000 times more potent than a control immunotoxin at inhibiting protein synthesis. In vivo, the maximum tolerated dose of i.t. immunotoxin was 10 micrograms. From the rate at which radiolabelled immunotoxins appeared in the plasma following i.t. injection, we were able to estimate that its half-life in the cerebrospinal fluid (CSF) was between 1 1/2 and 2 hr. Intrathecal treatment of guinea-pigs with immunotoxin 1 day after inoculation of L2C cells into the cisterna magna had a remarkable therapeutic effect. All guinea-pigs treated with 0.5 or 5 micrograms of immunotoxin survived, and remained tumour-free for more than 100 days after treatment, while control animals given cyclophosphamide alone or an irrelevant immunotoxin had a mean survival time of 28 days. Provided concerns over toxicity can be overcome, these results indicate that i.t. immunotoxins offer an alternative, highly specific form of treatment in leptomeningeal neoplasia.
Collapse
Affiliation(s)
- C E Urch
- Lymphoma Research Unit, Southampton General Hospital, UK
| | | | | | | | | | | | | |
Collapse
|
24
|
Lappi DA, Maher PA, Martineau D, Baird A. The basic fibroblast growth factor-saporin mitotoxin acts through the basic fibroblast growth factor receptor. J Cell Physiol 1991; 147:17-26. [PMID: 1645359 DOI: 10.1002/jcp.1041470104] [Citation(s) in RCA: 47] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
We have confirmed the hypothesis that a mitotoxin resulting from the conjugation of basic fibroblast growth factor and saporin exerts its cytotoxic effect through specific interaction with the basic fibroblast growth factor (FGF) receptor. Accordingly, the mitotoxin stimulates tyrosine phosphorylation of the 90 kD substrate that characterizes the initial cellular response to basic FGF. Cross-linking experiments show that radio-labeled basic fibroblast growth factor-saporin (FGF-SAP) binds to the receptor. Suramin, an inhibitor of growth factor receptor binding, inhibits the cytotoxicity of basic FGF-SAP. In a study of 4 different cell types, there is a decrease in the ED50 of the mitotoxin as the receptor number per cell increases. We have verified the cytotoxicity of the mitotoxin in 3 different assay systems. As expected, it is effective in the inhibition of protein synthesis and DNA synthesis, as well as of cell count. Binding of basic FGF-SAP which will result in cytotoxicity occurs very rapidly; 5 minutes of incubation of 10 nM basic FGF-SAP with cells results in 80% inhibition of cell count. The in vitro data indicate that the basic FGF-SAP is a receptor specific and potent suicide antagonist of basic FGF. Its potential as an anti-FGF for therapeutic and research uses in vivo is discussed.
Collapse
Affiliation(s)
- D A Lappi
- Department of Molecular and Cellular Growth Biology, Whittier Institute for Diabetes and Endocrinology, La Jolla, California 92037
| | | | | | | |
Collapse
|
25
|
Barbieri L, Battelli MG, Stirpe F. Blood clearance and organ distribution and tissue concentration of native, homopolymerized and IgG-conjugated ribosome-inactivating proteins. Xenobiotica 1990; 20:1331-41. [PMID: 2075751 DOI: 10.3109/00498259009046631] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
1. The blood clearance, organ distribution and tissue concentration of several native, homopolymerized, and IgG-conjugated 125I-labelled ribosome-inactivating proteins (RIPs) were determined in mice. 2. Native RIPs were cleared rapidly from blood, with half-lives of 4-8 min, and were concentrated mainly in the kidneys. 3. After conjugation to IgG the three RIPs studied showed increased blood half-lives and decreased concentrations in the kidneys. 4. The two homopolymers studied had blood half-lives and kidney concentrations intermediate to those of free and conjugated RIPs. 5. These results indicate that after IgG-conjugation the increased half-lives of the RIPs studied were at least in part due to the larger molecular size of the conjugates and to their lower renal excretion.
Collapse
Affiliation(s)
- L Barbieri
- Dipartimento di Patologia Sperimentale, Università di Bologna, Italy
| | | | | |
Collapse
|
26
|
Battelli MG, Barbieri L, Stirpe F. Toxicity of, and histological lesions caused by, ribosome-inactivating proteins, their IgG-conjugates, and their homopolymers. APMIS 1990; 98:585-93. [PMID: 2397111 DOI: 10.1111/j.1699-0463.1990.tb04975.x] [Citation(s) in RCA: 24] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
The toxicity of, and the lesions brought about by, several ribosome-inactivating proteins (bryodin, gelonin, momordin, pokeweed antiviral protein from seeds, saporin 6, trichokirin and momorcochin-S), either native, or conjugated to bovine IgG, or polymerized, were studied in the mouse. Severe necrotic liver damage was the main lesion present in animals receiving lethal doses of the proteins. The toxicity of ribosome-inactivating proteins increased after conjugation to IgG or homopolymerization. The toxicity of conjugates to mouse was not predictable from the inhibitory activity on cell-free protein synthesis.
Collapse
Affiliation(s)
- M G Battelli
- Dipartimento di Patologia Sperimentale, Università di Bologna, Italy
| | | | | |
Collapse
|
27
|
Wiley RG, Stirpe F, Thorpe P, Oeltmann TN. Neuronotoxic effects of monoclonal anti-Thy 1 antibody (OX7) coupled to the ribosome inactivating protein, saporin, as studied by suicide transport experiments in the rat. Brain Res 1989; 505:44-54. [PMID: 2575436 DOI: 10.1016/0006-8993(89)90114-5] [Citation(s) in RCA: 33] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
As a first attempt to develop suicide transport agents based upon antineuronal antibodies, we studied an immunotoxin directed against the Thy 1 antigen which is on rat neurons. The immunotoxin was composed of mouse monoclonal anti-Thy 1 antibody (OX7) and the ribosome-inactivating protein, saporin, and was prepared using the heterobifunctional cross linker, SPDP, which provides a disulfide linkage between the two protein components. This immunotoxin reliably and selectively destroyed ipsilateral vagal motor and sensory neurons after injection into the cervical vagus. Injection of the immunotoxin into the caudate nucleus produced destruction of the ipsilateral substantia nigra, pars compacta and intralaminar thalamic nuclei (parafascicular and central median). Anti-mouse IgG immunoperoxidase staining confirmed axonal transport of OX7 by vagal sensory and motor neurons and by caudate afferents and efferents. Systemic toxicity was not observed with OX7-saporin. The neuronotoxic effects of OX7-saporin were specific since injections of a similarly constructed immunotoxin of irrelevant specificity or a mixture of OX7 and saporin were without suicide transport activity. These results show the feasibility of using immunotoxins as suicide transport agents.
Collapse
Affiliation(s)
- R G Wiley
- Department of Neurology, Vanderbilt University, Nashville, TN
| | | | | | | |
Collapse
|
28
|
Bolognesi A, Barbieri L, Carnicelli D, Abbondanza A, Cenini P, Falasca AI, Dinota A, Stirpe F. Purification and properties of a new ribosome-inactivating protein with RNA N-glycosidase activity suitable for immunotoxin preparation from the seeds of Momordica cochinchinensis. BIOCHIMICA ET BIOPHYSICA ACTA 1989; 993:287-92. [PMID: 2597699 DOI: 10.1016/0304-4165(89)90178-5] [Citation(s) in RCA: 30] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
A ribosome-inactivating protein similar to those already known (Stirpe and Barbieri (1986) FEBS Lett. 195, 1-8) was purified from the seeds of Momordica cochinchinensis. This protein, for which the name of momorcochin-S is proposed, is a glycoprotein, has an Mr of approx. 30,000, and an alkaline isoelectric point and can be considered as an iso-form of the previously purified momorcochin from the roots of M. cochinchinensis. Momorcochin-S inhibits protein synthesis by a rabbit-reticulocyte lysate and phenylalanine polymerization by isolated ribosomes, and alters rRNA in a similar manner as the A-chain of ricin and related toxins (Endo et al. (1987) J. Biol. Chem. 262, 5908-5912). Momorcochin-S was linked to a monoclonal antibody (8A) against human plasma cells, and the resulting immunotoxin was selectively toxic to target cells.
Collapse
Affiliation(s)
- A Bolognesi
- Dipartimento di Patologia sperimentale, Università di Bologna, Italy
| | | | | | | | | | | | | | | |
Collapse
|
29
|
Dinota A, Barbieri L, Gobbi M, Tazzari PL, Rizzi S, Bontadini A, Bolognesi A, Tura S, Stirpe F. An immunotoxin containing momordin suitable for bone marrow purging in multiple myeloma patients. Br J Cancer 1989; 60:315-9. [PMID: 2789938 PMCID: PMC2247190 DOI: 10.1038/bjc.1989.277] [Citation(s) in RCA: 28] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023] Open
Abstract
Attempts have been made by a number of methods to eliminate minimal residual disease from bone marrow to be reinfused in autologous transplantation. In this paper we describe a conjugate containing a monoclonal antibody, named 8A, recognising a plasma cell-associated antigen, and momordin, a ribosome-inactivating protein similar to the ricin A-chain. This immunotoxin is active on target cell lines and on neoplastic plasma cells, while myeloid progenitors are fairly resistant. The conjugate is shown to be acceptable for ex vivo purging in autologous bone marrow transplantation in multiple myeloma patients.
Collapse
Affiliation(s)
- A Dinota
- Istituto di Ematologia Seràgnoli, Università di Bologna, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|